drugset / Trial / NCT06218628
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
Timeline
- Start
- 2024-04-05
- Primary completion
- 2029-08-22
- Completion
- 2030-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pacritinib | Small molecule | 200 mg | Oral |
| Subject | Talazoparib | Small molecule | 0.25 mg | Oral |
| Subject | Talazoparib | Small molecule | 0.5 mg | Oral |
| Subject | Talazoparib | Small molecule | 0.75 mg | Oral |
| Subject | Talazoparib | Small molecule | 1 mg | Oral |